Phase 3 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with a specific type of lung cancer called non-squamous non-small cell lung cancer (NSCLC), confirmed by a laboratory test on a tissue or cell sample.
• People whose lung cancer is at an advanced stage (Stage IIIB, IIIC, or Stage IV) and cannot be treated with surgery or a combination of chemotherapy and radiation aimed at curing the disease.
• People whose tumour does not have certain specific genetic changes (called EGFR mutations, ALK rearrangements, or ROS1 rearrangements), and who do not have a confirmed local test result showing any other genetic change for which targeted first-line treatments are already approved and available locally.
• People who are able to provide a tumour tissue sample so that certain markers on the tumour can be tested.
• People whose tumour shows a high level of a protein called PD-L1, with at least 50% of tumour cells testing positive for it.
• People who have at least one area of cancer in the body that has not previously been treated with radiation and can be measured according to standard guidelines.
• People who are in good general health, able to carry out normal daily activities, with at most minor symptoms affecting daily life (rated 0 or 1 on a standard health scale called the ECOG scale).
• People whose blood counts and organ function (such as liver and kidneys) are within acceptable levels.

Who may not be able to join:

• People who have already received systemic drug treatment (such as chemotherapy or immunotherapy) for advanced or metastatic NSCLC.
• People whose lung cancer is of the squamous cell type, mixed small cell type, or a rare form called sarcomatoid variant.
• People who have been diagnosed with another type of cancer within the past three years.
• People who have a history of, or currently have, certain immune system disorders or inflammatory conditions (some exceptions may apply — confirm with trial site).
• People with severe or poorly controlled health conditions that could make trial participation unsafe or difficult to manage.
• People with a significant build-up of fluid in body cavities (such as around the lungs) that cannot be drained repeatedly as needed.
• People who have a history of lung inflammation (called ILD or pneumonitis), including from radiation or medication, or who show signs of possible lung inflammation on scans at the time of screening (some exceptions may apply — confirm with trial site).
• People with significantly reduced lung function, as assessed by the treating doctor.
• People with cancer that has spread to and is compressing the spinal cord, or cancer that has spread to the brain and is still causing symptoms, is not stable on scans, or still requires steroids or anti-seizure medication.
• People who have had cancer spread to the membranes surrounding the brain and spinal cord (called leptomeningeal carcinomatosis).
• People with significant corneal eye disease.
• People with active tuberculosis, hepatitis B, hepatitis C, hepatitis A, or HIV that is not well managed.
• People with a history of a primary immune deficiency condition.

Important: Always verify eligibility with the trial site directly before applying.